Vera Therapeutics, Inc. · NASDAQ:VERA

Vera Therapeutics — J.P. Morgan Healthcare Conference 2025

26 slides from Vera Therapeutics's conference presentation, Jan 13, 2025

  1. Slide 1: J.P. Morgan Healthcare Conference

    Exhibit 99.1 J.P. Morgan Healthcare Conference January 13, 2025 © 2025 VERA THERAPEUTICS, INC.

  2. Slide 2: Forward-looking statements

    Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning of the Priva

  3. Slide 3: Atacicept potentially first and best-in-class dual BAFF/APRIL B cell modulator in IgAN

    Atacicept potentially first and best-in-class dual BAFF/APRIL B cell modulator in IgAN, with pipeline-in-a-product opportunity IgAN Potential Best-in-Class Potential Indication Expansion Resourced for Potential Launch • eGFR normalization may suggest • B cell modulation represents a • Currently ~$67

  4. Slide 4: Cumulative atacicept data to date supports best-in-class potential

    Cumulative Atacicept data to date supports best-in-class potential 1 2 3 Atacicept Sibeprenlimab Povetacicept Zigakibart Mechanism BAFF/APRIL inhibition APRIL inhibition only BAFF/APRIL inhibition APRIL inhibition only 25/75/150 mg SC QW (Phase 2) 2/4/8 mg/kg IV (Phase 2) 80/240 mg SC QM (Phase 1b)

  5. Slide 5: Strong Financial Position

    Strong Financial Position ~$677M ~63.4M Shares outstanding Cash, cash equivalents, (as of 11.21.24) and marketable securities 1 (pro forma unaudited as of 9.30.24) 1. Includes ~$353M of cash, cash equivalents and marketable securities as of September 30, 2024 and additional ~$324M in net proceeds fr

  6. Slide 6: Vera optionality to expand in autoimmune kidney disease & beyond

    Vera optionality to expand in autoimmune kidney disease & beyond US prevalence estimates ~230K Potential Future Indications 1-10 + ~70K Hematology ITP, AIHA, CAD, APS 1 ~160K Rheumatology Non-IgAN SLE, Sjogren’s, Long COVID autoimmune Neurology kidney disease MG PMN, FSGS, MCD and Metabolism Expande

  7. Slide 7: Atacicept Projected Catalysts

    Atacicept Projected Catalysts Catalyst 2025 2026 2Q Phase 3 full enrollment Phase 3 primary endpoint 2Q IgAN BLA submission 2H 1 Projected US launch IgAN Initial data Initiation IgAN, PMN, FSGS, MCD Initial data Vera holds worldwide, exclusive rights to develop and commercialize atacicept Based on m

  8. Slide 8: Dual BAFF/APRIL inhibition has broad therapeutic potential in autoimmune diseases

    Dual BAFF/APRIL inhibition has broad therapeutic potential to address multiple autoimmune diseases Immunity in health BAFF Antibodies bind to foreign antigens B cell APRIL Autoimmune disease Autoantigens and autoantibodies mediate BAFF autoimmune disease Autoantibodies bind to autoantigens B cells s

  9. Slide 9: Atacicept is an example of rational drug design

    Atacicept is an example of rational drug design Native TACI-Fc fusion: Soluble protein binds both BAFF and APRIL with nanomolar potency Atacicept BAFF APRIL BAFF APRIL 1 t =35 days 1/2 Kd Kd 2 2 1.45 nM 0.672 nM TACI TACI receptor receptor B cell Fc domain B cell of IgG1 Fc = fragment crystallizable

  10. Slide 10: ORIGIN Phase 2b long-term data at ASN Kidney Week and JASN

    ORIGIN Phase 2b long-term data revealed in late breaking oral presentation at ASN Kidney Week and JASN manuscript Double-Blind Treatment Open-label Extension Placebo n=30 Atacicept 25 mg QW n=15 Atacicept 150 mg QW Atacicept 75 mg QW n=30 Atacicept 150 mg QW n=30 Week 0 24 36 72 96 1° Endpoint 2° En

  11. Slide 11: 90% of participants completed atacicept treatment through 2 years

    90% of participants completed atacicept treatment through 2 years 232 screened 116 failed screening Randomized 116 randomized and treated double-blind treatment period 1 1 82 atacicept 34 placebo 2 3 2 discontinued treatment 3 discontinued treatment Completed week 36 and entered OLE 80 (98%) 31 (91%

  12. Slide 12: An ideal IgAN disease modifying therapy would be expected to…

    We believe an ideal IgAN disease modifying therapy would be expected to… Reduce Gd-IgA1 Resolve hematuria Reduce proteinuria Stabilize eGFR 12 © 2025 VERA THERAPEUTICS, INC.

  13. Slide 13: ORIGIN Phase 2b 96-week results consistent with IgAN disease modification

    ORIGIN Phase 2b 96-week results consistent with IgAN disease modification Including eGFR profile consistent with the general population of -1 mL/min/year Reduction in Gd-IgA1 Resolution of hematuria 0 0 -15 -20 -30 -40 -45 -60 -75% -60 -80 -66% -75 -100 0 12 24 36 48 60 72 96 0 12 24 36 48 60 72 84

  14. Slide 14: Atacicept treated participants have eGFR slope consistent with general population

    Atacicept treated participants have eGFR slope profile consistent with general population without kidney disease 4 Slope, mL/min/y 0 Atacicept ~ -0.6 General population ~ -1 1 estimate -4 IgAN natural history -8 including supportive 2 CKD therapy ~ -6 -12 0 12 24 36 48 60 72 84 96 Week This data is

  15. Slide 15: 2024 Draft KDIGO IgAN guidelines call for target eGFR slope ≤ -1 mL/min/year

    2024 Draft KDIGO IgAN guidelines call for target eGFR slope ≤ -1 mL/min/year 1 % patients who will reach kidney failure 0 25 50 75 100 -0.1 0 0 2 2 1 1 -0.5 25 17 19 15 6 8 -1 56 40 38 40 23 16 -2 100 89 80 78 60 26 2 Endothelin receptor antagonist ~ -3 -3 100 100 100 91 85 46 3 4 SGLT2i , corticost

  16. Slide 16: Discontinuation of atacicept increased Gd-IgA1 and decreased eGFR

    Discontinuation of Atacicept resulted in pronounced increase in Gd-IgA1 and decrease in eGFR, potentially supporting a paradigm of chronic treatment Gd-IgA1 % Change eGFR Change Last Atacicept Dose Last Atacicept Dose 150 0 -1 +117% 100 -2 -3 50 -4 -3.9 2 mL/min/1.73m 0 -5 96 +12 +26 96 +12 +26 Stud

  17. Slide 17: Consistency with ORIGIN 2b instills confidence in ORIGIN 3

    Consistency with ORIGIN 2b instills confidence in ORIGIN 3 Double-Blind Treatment Open-label Extension Placebo Atacicept 150 mg QW Atacicept 150 mg QW 156 Week 0 36 104 2° Endpoint 1° Endpoint eGFR: n=376 UPCR: n=200 Full enrollment 2Q 2025 expected Q2 2025 Fully enrolled Key Inclusion Criteria Key

  18. Slide 18: ORIGIN Extend: long-term access to atacicept

    ORIGIN Extend: Commitment to providing long-term access to atacicept for all ORIGIN participants Off treatment ORIGIN 2b Group 1 Atacicept 150 mg QW ORIGIN 3 Group 2 Week 0 156/Beyond • Phase 2 extension study in participants who complete ORIGIN 2b/3 • Objectives: 1. Provide patients with extended a

  19. Slide 19: Atacicept at home, self-administered QW dosing; QM program in 2025

    Atacicept at home, self-administered QW dosing highly attractive; QM program under way in 2025 • Biologic therapies utilizing at home, self-administered, vs SC 1 mL QW dosing have shown high compliance t • This dosing paradigm has the potential to support atacicept as a 1/2 1 foundational therapy fo

  20. Slide 20: Targeting B cell autoantibodies offers potential for additional kidney indications

    Targeting B cell production of autoantibodies against glomerular antigens offers the potential of additional kidney indications B Cell Activation Autoantibody Production Immune Complex Deposition Leading to Glomerulonephritis and Kidney Damage BAFF Anti-Gd-IgA1 antibodies IgAN B cell Anti-PLA2R anti

  21. Slide 21: PIONEER: Phase 2 basket trial in expanded IgAN and podocytopathies

    PIONEER: Phase 2 basket trial in expanded IgAN and anti-PLA2R & anti-nephrin podocytopathies Atacicept 150 mg QW Population 1, n ≤120 1 Expanded IgAN populations Week 0 36 52 1° Endpoint 2° Endpoint Key Endpoints Population 2, n ≤20 • Primary: UPCR change at week 36 Anti-PLA2R podocytopathy • Key se

  22. Slide 22: Established leadership in B cell modulation and expanded breadth of expertise

    Established leadership in B cell modulation and expanded breadth of expertise positions Vera for further innovation R&D Accomplishments Corporate Growth Jan 25 R&D Day: 72-week results Research & discovery ERA best abstract Bioassay and biomarkers ORIGIN FDA BTD for atacicept in IgAN Clinical pharma

  23. Slide 23: Opportunity to innovate and extend leadership in B cell modulation

    Opportunity to innovate and extend leadership in B cell modulation Current landscape of Monoclonal antibodies binding Fc fusion proteins containing either BAFF or APRIL alone TACI or TACI variants B cell modulators BAFF APRIL Atacicept Novel BCMA constructs Longest duration of represent an innovativ

  24. Slide 24: Novel, next-generation dual BAFF/APRIL inhibitor VT-109

    Novel, next-generation dual BAFF/APRIL inhibitor Potential for additional patient benefit across diseases and populations BAFF APRIL • Novel molecule engineered by team at Stanford University Atacicept VT-109 • Picomolar binding affinity for BAFF and APRIL, attractive PK and half-life • Novel compos

  25. Slide 25: Vera Pipeline

    Vera Pipeline Research & Discovery Preclinical Clinical Marketed Phase 3 IgAN Atacicept PMN, FSGS, MCD Phase 2 Potential future autoimmune indications Potential future VT-109 autoimmune indications MAU868 BK virus Phase 2 Vera holds worldwide, exclusive rights to develop and commercialize atacicept,

  26. Slide 26: © 2025 VERA THERAPEUTICS, INC.

    © 2025 VERA THERAPEUTICS, INC.

Vera Therapeutics — J.P. Morgan Healthcare Conference 2025 on 6ix